Gilead Pulls Back From Its Post-Earnings Peak, But the Street Is Still Lifting Targets

Gilead Sciences fell 1.7% on Tuesday to $167.47, giving back a slice of last week's 7.2% single-session earnings gain, while the consensus of analysts who cover it keeps moving in one direction: higher.

The post-earnings consolidation puts the stock roughly 2% below the consensus mean price target of $170.88, a gap that looked much larger before October 30. That day, ten firms raised targets simultaneously, all maintaining existing ratings. JP Morgan lifted to $190, Wells Fargo to $190, Morgan Stanley to $183, and UBS to $195. The highest marks came from Scotiabank at $200. Even RBC, the sole cautious voice at Sector Perform, moved its target from $126 to $131. The only dissent in the mix is structural: RBC's $131 target sits well below the current price, a gap worth watching as the stock approaches the top of the analyst range. The bull case rests on Biktarvy holding 53% of the US HIV treatment market, PrEP demand accelerating through Yeztugo and Descovy, and full-year product revenue guidance raised to $30.7 to $31.0 billion. The bear case is more specific: IRA price negotiations will cut the CMS price for Biktarvy's 30-day supply to $2,600 from 2027, implying roughly $1.5 billion in annual revenue pressure starting the following year.

Short interest gives no sign of renewed conviction on the negative side. At 1.6% of the free float, the short book is modest and has barely moved on the week. Borrow costs have more than halved over the past month to 0.27%, a reflection of how little urgency there is in the lending market. Availability is essentially unconstrained: with over 1.2 billion shares available to borrow against roughly 20 million sold short, there is no squeeze dynamic in play. Options positioning is similarly unthreatening. The put/call ratio is 0.65, slightly above its 20-day average of 0.62 but still well within the year's range of 0.40 to 0.92. The z-score of 0.81 points to mild caution, not conviction.

The week's most noteworthy insider activity reflects a planned sales cycle rather than a change in view. CEO Daniel O'Day filed sales totalling around $2.5 million across four tranches on November 2, all executed under a pre-arranged 10b5-1 plan, which limits the signal value of the transactions. He also exercised options on October 30 and sold the resulting shares at $175.25. The CFO and Chief Communications Officer both sold $469,000 worth of stock on October 15, also under 10b5-1 plans. Net insider activity over the past 90 days is negative at roughly $18.8 million, but the uniform use of pre-planned programmes means the sales are almost certainly scheduled disposals rather than directional calls.

Wikipedia attention for Gilead is running at a z-score of 2.36 against its own 90-day history, the highest retail engagement reading in the dataset's recent window. That aligns with the earnings coverage surge around October 29. None of Gilead's alt data series have been shown to lead its reported financials, so the attention spike is colour on the news cycle rather than a leading signal. What is worth watching is the next earnings event, flagged for November 6, two days away. The October 29 print itself generated the sharpest single-day stock move in recent quarterly history. With the annual IRA pricing question now on the table for 2027 and 2028, and the oral Yeztugo filing due before the FDA in February 2027, the November 6 event and any pipeline commentary around it are the specific items that would shift the current analyst consensus.